Trial · NCT07898566
Efficacy and Safety of CosmeRNA-ARI Anti Hair Loss Tonic in Adults With Androgenetic Alopecia
NCT07898566, Not applicable, Completed, BIONEER Corporation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of CosmeRNA-ARI Anti Hair Loss Tonic in Adults With Androgenetic Alopecia. Trials, record NCT07898566. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07898566
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of CosmeRNA-ARI Anti Hair Loss Tonic in Adults With Androgenetic Alopecia
- NCT number
- NCT07898566
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 90 participants, actual
- Lead sponsor
- BIONEER Corporation
- Conditions
- Androgenetic Alopecia
- Interventions
- Low-Concentration CosmeRNA-ARI Anti Hair Loss Tonic, High-Concentration CosmeRNA-ARI Anti Hair Loss Tonic, Vehicle Control Tonic Without CosmeRNA-AR
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Hair Density | Baseline to Week 8, Baseline to Week 16, and Baseline to Week 24 | Hair density was measured as the number of hairs per square centimeter in a designated scalp area using Folliscope 5.0. The same marked scalp area was assessed at baseline and after 8, 16, and 24 weeks of product use. Changes from baseline were compared among the low-concentration investigational product, high-concentration investigational product, and vehicle control groups. |
| Primary | Change From Baseline in Hair Thickness | Baseline to Week 8, Baseline to Week 16, and Baseline to Week 24 | Hair thickness was measured in millimeters using Folliscope 5.0. Three hairs within the designated scalp assessment area were selected for analysis. The same marked scalp area was assessed at baseline and after 8, 16, and 24 weeks of product use. Higher values indicated thicker hair. Changes from baseline were compared among the three study groups. |
| Primary | Change From Baseline in Hair Growth Rate | Baseline to Week 8, Baseline to Week 16, and Baseline to Week 24 | Hair growth rate was measured in millimeters per day using Folliscope 5.0. Three hairs within the designated scalp assessment area were selected for analysis. At baseline and after 8, 16, and 24 weeks of product use, paired images were obtained 2 days apart to calculate the daily hair growth rate. Higher values indicated faster hair growth. Changes from baseline were compared among the three study groups. |
| Secondary | Expert Global Assessment of Hair Growth | Week 8, Week 16, and Week 24 | Standardized photographs of the vertex and frontal hairline were independently evaluated by two experts using a 7-point global photographic assessment scale ranging from -3, indicating markedly worse, to +3, indicating markedly improved; 0 indicated no change from baseline. If the two experts assigned different scores, the lower score was used for analysis. Inter-rater reliability was evaluated using the intraclass correlation coefficient. Scores were compared among the low-concentration investigational product, high-concentration investigational product, and vehicle control groups. |
| Secondary | Participant-Reported Evaluation of Changes in Hair Loss Symptoms | Week 8, Week 16, and Week 24 | Participants evaluated perceived changes in overall hair loss symptoms, hair fullness at the vertex, the amount of shed hair, and the frontal hairline using a 7-point scale ranging from -3, indicating markedly worse, to +3, indicating markedly improved; 0 indicated no change. Responses of +1 to +3 were classified as positive responses. Results were summarized as the percentage of participants providing a positive response to each item. |
| Other | Incidence of Scalp Adverse Reactions | From baseline through Week 24 | Scalp adverse reactions were monitored throughout the study based on participant-reported symptoms, investigator examination, and adverse events observed or reported during product use. Investigator-assessed signs included erythema, edema, and papules. Participant-reported symptoms included itching, pricking pain, burning, tingling, and stiffness. The outcome was summarized as the number of participants with any scalp adverse reaction during product use. |
| Other | Product Use Compliance | From first product application through Week 24 | Compliance was calculated as the percentage of required product applications that were completed during the 24-week study period. Participants with compliance below 80% were considered noncompliant according to the prespecified criterion. |
| Other | Participant-Reported Scalp Symptoms | Baseline, Week 8, Week 16, and Week 24 | Participants rated scalp scaling, scalp sebum, and dandruff severity using a 5-point scale ranging from 0, indicating none, to 4, indicating severe. Lower scores indicated fewer scalp symptoms. Results were summarized for each item in the low-concentration investigational product, high-concentration investigational product, and vehicle control groups. |
| Other | Participant-Reported Product Acceptability | Week 24 | Participants evaluated product acceptability in terms of scalp moisturization, hair smoothness, spreadability, product scent, and overall user experience using a 5-point scale ranging from 0, indicating very poor, to 4, indicating very good. Results were summarized for each item in the low-concentration investigational product, high-concentration investigational product, and vehicle control groups. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07898566
GET https://conductscience.org/api/trials/v1/NCT07898566/registered